<DOC>
	<DOC>NCT02134834</DOC>
	<brief_summary>The objectives of this study are to assess the safety, tolerability and pharmacokinetic profile of OP0595 administered intravenously to healthy male, Caucasian, adult subjects at single escalating doses.</brief_summary>
	<brief_title>A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Caucasian males aged between 18 and 45 years (inclusive) at Screening A Body Mass Index (BMI) between 18.0 and 30.0 kg/mÂ² (inclusive) at Screening Good general health as determined by the Investigator based on medical history, physical examination, vital signs, 12lead ECG and clinical laboratory tests Negative urine test for drugs of abuse and breath test for alcohol both at Screening and Day 1 Receipt of any investigational agent or drug within four months before Screening A history or current evidence of allergic symptoms such as bronchial asthma, druginduced rash or urticaria Hypersensitivity and/or allergy to drugs Concurrent or history of clinically significant cardiovascular, hepatic, renal, endocrine, gastrointestinal, respiratory, psychiatric, neurologic and/or hematological disorders A history of chronic or recurrent infections or current active infection A recent history of surgery within three months prior to Screening, determined by the Investigator to be clinically relevant A history or presence of malignancy Donation of blood (or loss of blood) greater than 400 ml within three months before Screening A history of smoking at any time within one year before Screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>